Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues of human peripheral blood lymphocytes-SCID mice

被引:117
作者
Taub, DD
Longo, DL
Murphy, WJ
机构
[1] NCI,FREDERICK CANC RES & DEV CTR,SAIC,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702
[2] NCI,FREDERICK CANC RES & DEV CTR,CLIN SERV PROGRAM,FREDERICK,MD 21702
[3] NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,OFF ASSOCIATE DIRECTOR,FREDERICK,MD 21702
关键词
D O I
10.1182/blood.V87.4.1423.bloodjournal8741423
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The human cytokine, interferon-inducible protein-10 (IP-10), is a small glycoprotein secreted by activated monocytes, T cells, keratinocytes, astrocytes, and endothelial cells and is structurally related to the alpha subfamily of chemotactic cytokines called chemokines (Taub and Oppenheim, Cytokine 5:175, 1993). However, in contrast to other alpha chemokines that induce neutrophil migration, IP-10 has been shown to chemoattract monocytes and T lymphocytes in vitro, suggesting a role in T-cell-mediated immune responses. We therefore examined the effects of human IP-10 after in vivo administration. IP-10 induces significant mononuclear cell infiltration after subcutaneous injections in normal mice. In an effort to study the in vivo effects of IP-10 on human leukocyte migration, we then examined the ability of recombinant human IP-10 (rhIP-10) to induce human T-cell infiltration using a human/severe combined immune deficiency (SCID) mouse model. SCID mice received an intraperitoneal injection of human peripheral blood lymphocytes (10(8) cells), followed by a subcutaneous injection of rhIP-10 (1 mu g/injection) in the hind flank for 4 hours or sequential injections for 3 days. The skin and underlying tissue from the rhIP-10 injection site were then biopsied and examined for the extent of mononuclear cell infiltration. rhIP-10 again induced significant mononuclear cell accumulation 72 hours after injection. Immunohistologic evaluation determined that a significant number of human CD3(+) T cells were recruited in response to rhIP-10 injections. These results show that rhIP-10 is capable of inducing human T-cell migration in vivo and may play an important role in monocyte and lymphocyte recruitment into inflammatory sites.
引用
收藏
页码:1423 / 1431
页数:9
相关论文
共 37 条
[1]   HUMAN INTERFERON-INDUCIBLE PROTEIN-10 IS A POTENT INHIBITOR OF ANGIOGENESIS IN-VIVO [J].
ANGIOLILLO, AL ;
SGADARI, C ;
TAUB, DD ;
LIAO, F ;
FARBER, JM ;
MAHESHWARI, S ;
KLEINMAN, HK ;
REAMAN, GH ;
TOSATO, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :155-162
[2]   INTERLEUKIN (IL)-8-INDUCED INVITRO HUMAN LYMPHOCYTE MIGRATION IS INHIBITED BY CHOLERA AND PERTUSSIS TOXINS AND INHIBITORS OF PROTEIN KINASE-C [J].
BACON, KB ;
CAMP, RDR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 169 (03) :1099-1104
[3]  
BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97
[4]   MONOCYTE CHEMOATTRACTANT PROTEIN-1 ACTS AS A T-LYMPHOCYTE CHEMOATTRACTANT [J].
CARR, MW ;
ROTH, SJ ;
LUTHER, E ;
ROSE, SS ;
SPRINGER, TA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :3652-3656
[5]   IP-10, A GAMMA-INTERFERON-INDUCIBLE PROTEIN RELATED TO INTERLEUKIN-8, LACKS NEUTROPHIL ACTIVATING PROPERTIES [J].
DEWALD, B ;
MOSER, B ;
BARELLA, L ;
SCHUMACHER, C ;
BAGGIOLINI, M ;
CLARKLEWIS, I .
IMMUNOLOGY LETTERS, 1992, 32 (01) :81-84
[6]   EARLY MOLECULAR EVENTS IN THE INDUCTION-PHASE OF CONTACT SENSITIVITY [J].
ENK, AH ;
KATZ, SI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (04) :1398-1402
[7]   A 48-WELL MICRO CHEMOTAXIS ASSEMBLY FOR RAPID AND ACCURATE MEASUREMENT OF LEUKOCYTE MIGRATION [J].
FALK, W ;
GOODWIN, RH ;
LEONARD, EJ .
JOURNAL OF IMMUNOLOGICAL METHODS, 1980, 33 (03) :239-247
[8]  
GOMEZCHIARRI M, 1993, AM J PATHOL, V142, P433
[9]   DETECTION OF A GAMMA-INTERFERON-INDUCED PROTEIN IP-10 IN PSORIATIC PLAQUES [J].
GOTTLIEB, AB ;
LUSTER, AD ;
POSNETT, DN ;
CARTER, DM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (03) :941-948
[10]  
ISSEKUTZ TB, 1995, FASEB J, V9, P1564